News

In March 2023, the ALS Society of Canada and Brain Canada announced the latest round of Discovery Grant recipients from their 2022 research grant competition. With support from SLA Québec and the Dr. Jean-Pierre Canuel Fund, nine Canadian researchers and…

The province of Ontario has listed RADICAVA Oral Suspension (edaravone), also known as oral edaravone, on the public formulary as a therapy accessible through the Ontario Drug Benefit Program’s Exceptional Access Program (EAP) as a treatment for ALS. This decision…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the July 2023 Research Update, you’ll learn about the role genetic factors may play…

Last updated: November 7, 2023 July 20, 2023 – Mitsubishi Tanabe Pharma Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully concluded negotiations for RADICAVA Oral Suspension (edaravone), also known as oral edaravone, and entered into a Letter of Intent…

The province of Ontario has listed ALBRIOZA on the public formulary as a therapy accessible through the Ontario Drug Benefit Program’s Exceptional Access Program (EAP) as a treatment for ALS. This decision comes quickly after the conclusion of the pCPA…

Updated on November 27, 2023 June 15, 2023 – Amylyx and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully concluded negotiations for ALBRIOZA and entered into a Letter of Intent (LOI) for the terms and conditions under which ALBRIOZA would qualify…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

With admiration and gratitude, the ALS Society of Canada (ALS Canada) acknowledges the incredible contribution of our Board member, Dr. Christine Vande Velde, whose term has come to an end.     Dr. Vande Velde leaves her position on the Board…